Thyroid Function Tests Assessment in Patients with Chronic Obstructive Pulmonary Disease
Abstract
BACK GROUND: Chronic obstructive pulmonary disease (COPD) is the term used to describe slowly progressive airways obstruction, usually associated with smoking, that is not reversible and associated with lifelong morbidity with metabolic and several endocrine disturbances.
AIM OF STUDY: To evaluate thyroid function tests (TFT) in patients with COPD.
PATIENTS AND METHODS: Pulmonary function test (PFT) was done to 40 patients with obstructive lung disease and twenty age and sex matched healthy control individuals to confirm diagnosis of COPD and assess the severity of disease.
For all these patients SPO2 with oximetry was measured and TT3, TT4 and TSH were assessed with ELISA test.
RESULTS: The values of PFT (vital capacity, forced vital capacity, forced expiratory volume in 1s and peak expiratory flow), TSH and SPO2 were lower in the COPD than control group (P value 0.001).
In severe COPD (FEV1 < 50%) there was a significant reduction in T3 but not T4 or TSH in comparison with mild-moderate COPD patients.
CONCLUSION: Thyroid dysfunction is observed in patients with COPD, and with increasing severity of COPD, there is a decrease in all thyroid function parameters pointing to a metabolic response, and patients with lower weight indices have lower drive for TSH and consequently T3..
References
1. Worled Health Organization: World Health Report. Geneva, Word Health Organization,2000.
2. Roberto R, Antonio A, Jean B et al. Pocket Guide to COPD diagnosis, management and prevention: Global Initiative for Chronic Obstructive Lung Disease (GOLD) updated 2010.
3. Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Euro Respir J 1995; 8: 1398-1420.
4. Beers MH, Berkow R: The Merck Manuel, ed 17. Whitehouse Station, Merck, 1999, р 575.
5. Meek PM, Schwartz stein RM, Adams L, et al. Dyspnea - mechanisms, assessment, and management: A consensus statement. Am J Respir Crit Care Med 1999; 159: 321-340.
6. Rabe KF et al: Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 176:532, 2007.
7. Pauwels RA et al: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 163:1256, 2001.
8. Bratel T, Wennlund A, Carlstrom K: Impact of hypoxemia on neuroendocrine function and catecholamine secretion in chronic obstructive pulmonary disease (COPD): Effects of long-term oxygen treatment. Respir Med 2000; 94:1221-1228.
9. Gow SM, Seth J, Beckett GJ, Douglas G: Thyroid function and endocrine abnormalities in elderly patients with severe chronic obstructive lung disease. Thorax 1987; 42:520-525.
10. Semple PD, Beastall GH, Waston WS, Hume R: Hypothalamic – pituitary dysfunction in respiratory hypoxia. Thorax 1981; 36:605-609.
11. Yen PM. Genomic and nongenomic actions of thyroid hormones. In: Braverman LE, Utiger RD. The thyroid. A fundamental and clinical text, 9th ed Lippincott Williams and Wilkins, Philadelphia 2005; pp 135-150.
12. Silva JE. Intermediary metabolism and the sympathoadrenal system in hypothyroidism. In: Braverman LE, Utiger RD. The thyroid. A fundamental and clinical text, 9th ed Lippincott Williams and Wilkins, Philadelphia 2005; pp 817- 823.
13. Silva JE. Thermogenesis and sympathoadrenal system in thyrotoxicosis. In: Braverman LE, Utiger RD. The thyroid. A fundamental and clinical text, 9th ed Lippincott Williams and Wilkins, Philadelphia 2005; pp 607- 620.
14. Saaresranta T, Polo O. Hormones and breathing. Chest 2002;122:2165-2182.
15. Karadag F, Ozcan H, Karul AB, et al. Correlates of nonthyroidal illness syndrome in chronic obstructive pulmonary disease. Respir Med 2007;101:1439- 1446.
16. Dimopoulou I, Elias I, Mastorakos G, Mantzos E, Roussos C, Koutras DA. Effects of severity of chronic obstructive pulmonary disease on thyroid function. Metabolism 2001; 50: 1397-1401.
17. De Groot L J: Dangerous dogmas in medicine: The non thyroidal illness syndrome. J Clin Endocrinol Metab 84:151- 164, 1999.
18. Chopra IJ : Clinical Review 86: Euthyroid sick syndrome: Is it a misnomer? J Clin Endocrinol Metab 82:329-334, 1997.
19. Opasich C, Pacini F, Ambrosino N, et al: Sick euthyroid syndrome in patients with moderate-to-severe chronic heart failure. Euro Heart J 17:1860-1866, 1996.
20. Boelen A, Platvoet-Ter Schiphorst MC, Wiersinga WM: Association Between serum interleukin-6 and serum 3,5,3? Triiodothyronine in nonthyroidal illness. J Clin Endocrinol Metab 77:1695-1699, 1993.
21. Arnaout MA, Nastallah NS, el-Khateeb MS: Prevalence of abnormal Thyroid function tests in connective tissue disease. Scand J Rheumatol 23:128-132, 1994.
22. Boelen A, Platvoet-Ter Schiphorst MC, Wiersinga WIM: Association Between serum interleukin-6 and serum 3,5,3°-triodothyronine in nonthyroidal illness. J Clin Endocrinol Metab 77:1695-1699, 1993.
23. Le JM, Vilcek J: Interleukin-6: A multifunctional cytokine regulating immune reactions and the acute phase protein response. Lab Invest 61:588- 602, 1989.
24. Stouthard JM, van der Poll T, Endert E, et al: Effects of acute and Chronic interleukin-6 administration on thyroid hormone metabolism in Humans. J Clin Endocrinol Metab 79:1342-1346, 1994.
25. Hashimoto H, Igarashi N, Yachie A, et al: The relationship between serum levels of interleukin-6 and thyroid hormone in children With acute respiratory infection. J Clin Endocrinol Metab 78:288-291, 1994.
